A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 18 Jun 2025
At a glance
- Drugs GT-103 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Jun 2025 New trial record